Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an investigator-initiated, industry-funded, multi-centre, international study that will be carried out prospectively at hemophilia treatment centres across Canada, the Czech Republic and Australia with SickKids as the coordinating site. The study will use a central laboratory not directly affiliated with any of the participating sites. Enrollment target is 50 participants, both adult and pediatric with severe hemophilia A receiving Advate, who will each complete a 2-point and 6-point pharmacokinetic (PK) sampling. The main aim is to compare the results of a 2 sample PK using clinically practical time points and myPKFiT™ (a web-based, population PK Bayesian tool) to a 6 sample population PK to determine whether the results obtained are in good agreement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Canadian Hemophilia Prophylaxis Study

NCT01085344

Severe Hemophilia A

COMPLETED PHASE4

An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia

NCT02199717

Hemophilia A Hemophilia B Factor VIII Deficiency +1 more

COMPLETED

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385

Hemophilia A

WITHDRAWN PHASE4

Genetic Susceptibility to Factor VIII Inhibitors

NCT00344435

Hemophilia

COMPLETED

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301

Blood Coagulation Disorder Blood Coagulation Disorders, Inherited Coagulation Protein Disorders +6 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2-point and 6-point PK sampling

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of Hemophilia A;
* Severe disease (FVIII \<2%);
* Receiving ADVATE for prevention of bleeding (prophylaxis) or receiving ADVATE on demand and a candidate for prophylaxis;
* Body weight ≤120 kg; and ≥12kg;

Exclusion Criteria

* FVIII inhibitor positive (level of ≥0.6 Bethesda Units \[BU\] per mL using the Nijmegen modification of the Bethesda assay). Inhibitor status to be documented as negative prior to study enrollment according to the two most recent, consecutive inhibitor assays on record. If patients have \< 50 exposure days, an assay will be completed centrally within a reasonable timeframe (approximately 8 weeks suggested) to make sure that they are negative.
* Body weight \>120 kg or \<12kg;
* Human immunodeficiency virus (HIV) positivity with cluster of differentiation 4 (CD4) count \< 200 / microliter;
* Significant hepatic dysfunction, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times upper limit of normal
* History of recent events that might affect FVIII half-life (e.g., infection, surgery or an invasive procedure) within 2 weeks of blood sampling.

Eligible Sex

ALL

Accepts Healthy Volunteers

No